Lyon, December 07, 2010 - The BioVision Lilly Award, in conjunction with TWAS, the academy of
sciences for the developing world, will honour outstanding scientific achievements made by individual
young scientists from developing countries.
The prize will reward three young scientists living and working in a developing country, who have a track
record of excellent research in infectious diseases, with an emphasis on tuberculosis preferred, and
promise to have a positive impact in the developing world.
Candidates should be nationals of a developing country, under 40 years of age and hold at least a PhD
degree with an outstanding academic background.
Three winners will be selected and invited to attend BioVision 2011 in Lyon, France from March 27-29.
The winner and the first runner up will each receive funding to be used for his or her research.
The awards will be presented at a ceremony hosted by BioVision, TWAS and Lilly, during BioVision 2011.
Additional information and nomination forms are available from the TWAS Secretariat:
email@example.com or on the TWAS website at this link www.twas.org > Programmes > Prizes
About BioVision, the Lilly MDR-TB Partnership and TWAS
TWAS, the academy of sciences for the developing world is an autonomous international organization
founded in Trieste, Italy in 1983. TWAS represents the best of science in the developing world. Its
principal aim is to promote scientific capacity and excellence for sustainable development in the South.
The administration and financial operation of TWAS is undertaken by UNESCO in accordance with an
agreement signed by the two organizations.
BioVision 2011 will take place on March 27-29 in Lyon, France. BioVision engages key international
leaders from different backgrounds in debates on global issues involving science and society. Every other
year in Lyon, BioVision brings together government and business leaders, scholars, policy makers and
NGO directors. Participants analyze scientific breakthroughs, pressing global challenges, discuss the most
effective solutions, and build lasting partnerships that enable them to create positive social change.
The Lilly MDR-TB Partnership
Recognizing that MDR-TB cannot be halted by medicine alone, Lilly created the Lilly MDR-TB Partnership
in 2003. This public-private initiative mobilizes over 20 partners on five continents to tackle the scourge
of TB and MDR-TB. Eli Lilly and Company is contributing US$ 120 million in cash, medicines, advocacy
tools and technology to focus global resources on prevention, diagnosis and treatment of TB and MDR-
TB. An additional US$ 15 million was given to the Lilly TB Drug Discovery Initiative; a nonprofit with the
goal of accelerating the discovery of new drugs to treat TB by bringing together specialists from around
the world. The company has made this investment to ensure that thousands of MDR-TB patients receive
the care and medication they need to combat this disease.
BioVision: Alize PR :
Aurélie Bellemin Caroline Carmagnol